Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
- PMID: 19246508
- DOI: 10.1093/jac/dkp034
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial
Abstract
Objectives: This prospective study was designed to determine the efficacy of a levofloxacin-based rescue therapy for Helicobacter pylori infection after failure of standard triple therapies. We also surveyed the predictors of this rescue therapy.
Patients and methods: From June 2005 to March 2007, 1036 patients infected with H. pylori received standard triple regimens (proton pump inhibitor, clarithromycin and amoxicillin). H. pylori eradication was achieved in 855 (82.5%) subjects. One hundred and sixty-six eradication-failure patients were enrolled and randomly assigned to receive a 7 day eradication therapy with esomeprazole, bismuth subcitrate, tetracycline and metronidazole (EBTM) or esomeprazole, amoxicillin and levofloxacin (EAL). Follow-up endoscopy was done 16 weeks later to assess the treatment response. Patients' response, CYP2C19 genotypes and antibiotic resistances were also examined.
Results: Intention-to-treat analysis revealed that both groups showed similar eradication rates [EBTM 63.9%; 95% confidence interval (CI): 53.6-74.2 and EAL 69.9%; 95% CI: 60.1-79.7] (P = 0.89). Per-protocol results were EBTM = 84.1% (95% CI: 75.1-93.1) and EAL = 75.3% (95% CI: 65.8-84.8) (P = 0.82). Both regimens had similar compliance (P = 0.32), but the EBTM group had more adverse events (P = 0.27). Logistic regression analysis showed that poor compliance, CYP2C19 homozygous extensive metabolizer genotype and levofloxacin resistance were important predictors for eradication failure.
Conclusions: The EAL regimen can achieve an efficacy similar to that of the standard EBTM therapy. It may be very useful in countries where bismuth salts are not available. Compliance, CYP2C19 genotype and resistances to antibiotics may influence the outcome of levofloxacin-based rescue therapy. It seems advisable to reserve levofloxacin for rescue treatment to avoid an increase in the resistance phenomenon.
Similar articles
-
Randomized comparison of two rescue therapies for Helicobacter pylori infection.Eur J Clin Invest. 2006 Nov;36(11):803-9. doi: 10.1111/j.1365-2362.2006.01725.x. Eur J Clin Invest. 2006. PMID: 17032348 Clinical Trial.
-
Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.J Antimicrob Chemother. 2013 Jan;68(1):222-8. doi: 10.1093/jac/dks361. Epub 2012 Sep 14. J Antimicrob Chemother. 2013. PMID: 22984204 Clinical Trial.
-
Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.Helicobacter. 2012 Jun;17(3):216-23. doi: 10.1111/j.1523-5378.2012.00937.x. Epub 2012 Mar 20. Helicobacter. 2012. PMID: 22515360 Clinical Trial.
-
'Rescue' therapies for the management of Helicobacter pylori infection.Dig Dis. 2006;24(1-2):113-30. doi: 10.1159/000090315. Dig Dis. 2006. PMID: 16699270 Review.
-
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).Expert Opin Pharmacother. 2013 May;14(7):843-61. doi: 10.1517/14656566.2013.782286. Epub 2013 Mar 29. Expert Opin Pharmacother. 2013. PMID: 23537368 Review.
Cited by
-
Second-line rescue treatment of Helicobacter pylori infection: Where are we now?World J Gastroenterol. 2018 Oct 28;24(40):4548-4553. doi: 10.3748/wjg.v24.i40.4548. World J Gastroenterol. 2018. PMID: 30386104 Free PMC article. Review.
-
Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.Wien Klin Wochenschr. 2010 Jul;122(13-14):413-22. doi: 10.1007/s00508-010-1404-3. Epub 2010 Jul 16. Wien Klin Wochenschr. 2010. PMID: 20628905
-
Testing for Helicobacter pylori in an era of antimicrobial resistance.J Clin Microbiol. 2024 Feb 14;62(2):e0073223. doi: 10.1128/jcm.00732-23. Epub 2024 Jan 9. J Clin Microbiol. 2024. PMID: 38193664 Free PMC article. Review.
-
Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.World J Gastroenterol. 2012 Oct 28;18(40):5669-78. doi: 10.3748/wjg.v18.i40.5669. World J Gastroenterol. 2012. PMID: 23155306 Free PMC article. Review.
-
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.Biomed Res Int. 2015;2015:163960. doi: 10.1155/2015/163960. Epub 2015 May 18. Biomed Res Int. 2015. PMID: 26090383 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical